ONL logo.jpg
ONL Therapeutics Closes $65 Million in Oversubscribed Series D Financing
13. September 2024 07:00 ET | ONL Therapeutics
ANN ARBOR, Mich., Sept. 13, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL logo.jpg
ONL Therapeutics to Present at the 57th Annual Scientific Meeting of The Retina Society and EURETINA Innovation Spotlight
10. September 2024 07:00 ET | ONL Therapeutics
ANN ARBOR, Mich., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
Full Logo - OKYO .jpg
OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use
06. August 2024 07:00 ET | OKYO Pharma LTD
LONDON and NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
ONL logo.jpg
ONL Therapeutics to Present at 2024 BIO CEO & Investor Conference
06. Februar 2024 07:00 ET | ONL Therapeutics
ANN ARBOR, Mich., Feb. 06, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL logo.jpg
ONL Therapeutics to Present on ONL1204 in Podium Presentation at the 47th Annual Meeting of the Macula Society
23. Januar 2024 07:00 ET | ONL Therapeutics
ANN ARBOR, Mich., Jan. 23, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL logo.jpg
ONL Therapeutics Completes Enrollment in Phase 2 Study of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment
28. August 2023 07:00 ET | ONL Therapeutics
More than 135 patients recruited in four months for Phase 2 study of a single intravitreal (IVT) injection of ONL1204 Ophthalmic Solution as adjunct to standard-of-care surgery Topline data readout...
ONL logo.jpg
ONL Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment
12. April 2023 07:00 ET | ONL Therapeutics
ANN ARBOR, Mich., April 12, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL logo.jpg
ONL Therapeutics to Report Clinical Data on ONL1204 in Podium Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
11. April 2023 07:00 ET | ONL Therapeutics
Presentation will review the results of ONL’s Phase 1 study of ONL1204 Ophthalmic Solution in patients with Macula-Off Rhegmatogenous Retinal Detachment Preclinical data in models of inherited...
ONL logo.jpg
ONL Therapeutics Closes First Tranche of $15 Million Series C Financing to Advance Lead Compound into Phase 2 Clinical Trial
08. März 2023 07:00 ET | ONL Therapeutics
ANN ARBOR, Mich., March 08, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
The Dry Eye Drink by Bruder
Bruder Healthcare Now Exclusive Licensor of the Dry Eye Drink™ -- First and Only Ophthalmic Anti-Inflammatory Hyper-Hydrating Drink
13. Februar 2023 10:00 ET | Bruder Healthcare
ATLANTA, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Bruder Healthcare, a Hilco Vision Company, announced an exclusive licensing agreement with Baton Rouge-based Dry Eye Drink LLC, the manufacturer of a...